TY - JOUR AB - Although human epidermal growth factor receptor 2 (HER2)‑targeted therapy significantly improves the prognosis of patients with HER2‑positive breast cancer, most patients with advanced breast cancer eventually progress due to drug resistance. At present, there is no standard treatment after patients become resistant to HER2‑targeted therapy. Previous studies have indicated that anti‑angiogenesis drugs have potential efficacy in the treatment of advanced breast cancer. The present study reported on a case of a pretreated patient with HER2‑positive advanced breast cancer with brain metastases who developed resistance to multiple lines of HER2‑targeted treatment. The patient was treated with apatinib combined with trastuzumab and albumin‑bound paclitaxel. The patient achieved partial response to the third‑line treatment with a progression‑free survival of 9 months. After combination treatment, the symptoms of headache and vomiting were relieved and all the brain metastases were significantly reduced. The present case indicated that apatinib may have anti‑tumor activity in patients with HER2‑positive breast cancer with HER2‑targeted drug resistance. The present case provides valuable information and may offer a new possibility for the treatment of patients with breast cancer with brain metastases who progressed after clinical treatment with small‑molecule anti‑HER2 tyrosine kinase inhibitor drugs. AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China AU - Huang,Jiayi AU - Chen,Xiao AU - Guo,Jinfeng AU - Song,Lin AU - Mu,Yanxi AU - Zhao,Han AU - Du,Caiwen DA - 2023/02/01 DO - 10.3892/ol.2022.13642 IS - 2 JO - Oncol Lett KW - HER2 positive breast cancer apatinib brain metastases angiogenesis case report PY - 2023 SN - 1792-1074 1792-1082 SP - 56 ST - Apatinib combined with trastuzumab and albumin‑bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti‑HER2 TKIs: A case report T2 - Oncology Letters TI - Apatinib combined with trastuzumab and albumin‑bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti‑HER2 TKIs: A case report UR - https://doi.org/10.3892/ol.2022.13642 VL - 25 ER -